Pathos AI collects $365M to fuel 'bulletproof' oncology trials and in-license more cancer drugs

Kyle LaHucik

Senior Reporter

Pathos AI, seeking to upend cancer drug development with artificial intelligence and large multimodal models, has raised the third-largest private funding round in biotech so …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Pathos AI collects $365M to fuel 'bulletproof' oncology trials and in-license more cancer drugs

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

The inside story of the six-month sprint to create the first custom CRISPR therapy for one infant’s rare disease

Exclusive: Drug compounder Empower was built on risky shortcuts, ex-employees and inspections allege

Bristol Myers CEO says America’s biopharma pole position is not guaranteed

Biohaven stock sinks on three-month delay for neuro drug's FDA approval decision

New CBER chief Prasad is readying 'massive framework' around vaccines, Makary says

Updated: Merck KGaA continues US tariff surcharge but at a 'decreased' rate

Pathos AI col­lects $365M to fu­el 'bul­let­proof' on­col­o­gy tri­als and in-li­cense more can­cer drugs

Senior Reporter

Sign up to read this article for free.

more like this

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Pathos AI collects $365M to fuel 'bulletproof' oncology trials and in-license more cancer drugs